Angiotensin II AT 1 receptor blockers as treatments for inflammatory brain disorders

Clinical Science

Volumn 123, Issue 10, 2012, Pages 567-590

  Saavedra, Juan M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Angiotensin II type 1 receptor blocker (ARB); Brain; Inflammation; Neuronal injury; Renin angiotensin system

Indexed keywords

AMLODIPINE; AMYLOID BETA PROTEIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXP 3179; IMIDAZOLE DERIVATIVE; IRBESARTAN; LOSARTAN; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR BLOCKER; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PROPRANOLOL; ROSIGLITAZONE; SARTAN DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TELMISARTAN; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VALSARTAN; ANGIOTENSIN II; BIOLOGICAL MARKER; NEUROPROTECTIVE AGENT;

AGING; ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; BRAIN BLOOD FLOW; BRAIN CIRCULATION; BRAIN DISEASE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DEGENERATIVE DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE COURSE; DRUG STRUCTURE; ENCEPHALITIS; ENDOTHELIUM CELL; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; METABOLIC SYNDROME X; MICROGLIA; MONOCYTE; MOOD DISORDER; MULTIPLE SCLEROSIS; NERVE CELL; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; RADIATION INJURY; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; STOMACH ULCER; STRESS; TRAUMATIC BRAIN INJURY; VASCULAR ENDOTHELIUM; BRAIN; BRAIN INJURY; DRUG EFFECT; METABOLISM; PHYSIOLOGICAL STRESS; PHYSIOLOGY; REVIEW; STROKE; VASCULARIZATION;

AGING; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL MARKERS; BRAIN; BRAIN DISEASES; BRAIN INJURIES; BRAIN ISCHEMIA; HUMANS; INFLAMMATION; MOOD DISORDERS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; STRESS, PHYSIOLOGICAL; STROKE;

EID: 84866788499     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120078     Document Type: Article

References (263)

1. Andriessen, T. M., Jacobs, B. and Vos, P. E. (2010) Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury. J. Cell. Mol. Med. 14, 2381-2392
2. Barnes, D. E. and Yaffe, K. (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 10, 819-828
3. Bostwick, J. M. (2010) A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. Mayo Clin. Proc. 85, 538-550
4. Nimmo, A. J. and Vink, R. (2009) Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat. CNS Drug Discovery. 4, 86-95
5. Zanchetti, A. and Elmfeldt, D. (2006) Findings and implications of the Study on Cognition and Prognosis in the Elderly (SCOPE): a review. Blood Pressure. 15, 71-79
6. Savoia, C. and Schiffrin, E. L. (2007) Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin. Sci. 112, 375-384
7. Burgess, E., Muirhead, N., de Cotret, P. R., Chiu, A., Pichette, V. and Tobe, S. (2009) Supramaximal dose of candesartan in proteinuric renal disease. J. Am. Soc. Nephrol. 20, 893-900
8. McFarlane, S. I. (2009) Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials. Expert Rev. Cardiovasc. Ther. 7, 1363-1371
9. Ismail, H., Mitchell, R., McFarlane, S. I. and Makaryus, A. N. (2010) Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering. Curr. Diabetes Rep. 10, 32-36
10. Johnson, A. K. and Grippo, A. J. (2006) Sadness and broken hearts: neurohumoral mechanisms and co-morbidity of ischemic heart disease and psychological depression. J. Physiol. Pharmacol. 57 (Suppl. 11), 5-29
11. Axon, R. N., Zhao, Y. and Egede, L. E. (2010) Association of depressive symptoms with all-cause and ischemic heart disease mortality in adults with self-reported hypertension. Am. J. Hypertens. 23, 30-37
12. Maes, M., Kubera, M., Obuchowiczwa, E., Goehler, L. and Brzeszcz, J. (2011) Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. NeuroEndocrinol. Lett. 32, 7-24
13. Salzet, M., Deloffre, L., Breton, C., Vieau, D. and Schoofs, L. (2001) The angiotensin system elements in invertebrates. Brain Res. Rev. 36, 35-45
14. Szczepanska-Sadowska, E., Cudnoch-Jedrzejewska, A., Ufnal, M. and Zera, T. (2010) Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J. Physiol. Pharmacol. 61, 509-521
15. Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W. and Kelley, K. W. (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46-56
16. Sparkman, N. L. and Johnson, R. W. (2008) Neuroinflammation associated with aging sensitizes the brain to the effects of infection or stress. NeuroImmunoModulation. 15, 323-330
17. Glass, CK., Saijo, K., Winner, B., Marchetto, M. C. and Gage, F. H. (2010) Mechanisms underlying inflammation in neurodegeneration. Cell. 140, 918-934
18. Tansey, M. G. and Goldberg, M. S. (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37, 510-518
19. Marchesi, VT. (2011) Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J. 25, 5-13
20. Licinio, J. and Wong, M.-L. (1997) Pathways and mechanisms for cytokine signaling of the central nervous system. J. Clin. Invest. 100, 2941-2947
21. Strandgaard, S. and Paulson, O. B. (1992) Regulation of cerebral blood flow in health and disease. J. Cardiovasc. Pharmacol. 19 (Suppl. 6), S89-S93
22. Farrall, A. J. and Wardlaw, J. M. (2009) Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol. Aging. 30, 337-352
23. McEwen, B. S. (2008) Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. Eur. J. Pharmacol. 583, 174-185
24. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., Eikelenboom, P., Emmerling, M., Fiebich, B. L. et al. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging. 21, 383-421
25. Letiembre, M., Hao, W., Liu, Y., Walter, S., Mihaljevic, I., Rivest, S., Hartmann, T. and Fassbender, K. (2007) Innate immune receptor expression in normal brain aging. Neuroscience. 146, 248-254
26. Denes, A., Thornton, P., Rothwell, N. J. and Allan, S. M. (2010) Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation. Brain Behav. Immun. 24, 708-723
27. Sastre, M., Richardson, J. C., Gentleman, S. M. and Brooks, D. J. (2011) Inflammatory risk factors and pathologies associated with Alzheimer's disease. Curr. Alzheimer Res. 8, 132-141
28. Saavedra, J. M., Sánchez-Lemus, E. and Benicky, J. (2011) Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications. Psychoneuroendocrinology. 36, 1-18
29. Rivest, S. (2010) Interactions between the immune and neuroendocrine systems. Prog. Brain Res. 181, 43-53
30. Quan, N. and Banks, W. A. (2007) Brain-immune communication pathways. Brain Behav. Immun. 21, 727-735
31. Hanke, M. L. and Kielian, T. (2011) Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin. Sci. 121, 367-387
32. Guha, M. and Mackman, N. (2001) LPS induction of gene expression in human monocytes. Cell. Signalling. 13, 85-94
33. Sánchez-Lemus, E., Murakami, Y., Larrayoz-Roldan, I. M., Moughamian, A. J., Pavel, J., Nishioku, T. and Saavedra, J. M. (2008) Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland. Endocrinology. 149, 5177-5188
34. Murck, H., Schüssler, P. and Steiger, A. (2012) Renin-angiotensin-aldosterone system: the forgotten stress hormone system: relationship to depression and sleep. Pharmacopsychiatry. 45, 83-95
35. Grossmann, C. and Gekle, M. (2009) New aspects of rapid aldosterone signaling. Mol. Cell. Endocrinol. 308, 53-62
36. Felder, RB. (2010) Mineralocorticoid receptors, inflammation and sympathetic drive in a rat model of systolic heart failure. Exp. Physiol. 95, 19-25
37. Gomez-Sanchez, E. P. (2011) Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule? Trends Endocrinol. Metab. 22, 179-187
38. Singh, A. K. and Jiang, Y. (2004) How does peripheral lipopolysaccharide induce gene expression in the brain of rats? Toxicology 201, 197-207
39. Duvernoy, H. M. and Risold, P. Y. (2007) The circumventricular organs: an atlas of comparative anatomy and vascularization. Brain Res. Rev. 56, 119-147
40. Henry, C. J., Huang, Y., Wynne, A. M. and Godbout, J. P. (2009) Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1β and anti-inflammatory IL-10 cytokines. Brain Behav. Immun. 23, 309-317
41. Danielyan, L., Lourhmati, A., Verleysdonk, S., Kabisch, D., Proksch, B., Thiess, U., Umbreen, S., Schmidt, B. and Gleiter, C. H. (2007) Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNFα release. Neurochem. Res. 32, 1489-1498
42. Lanz, T. V., Ding, Z., Ho, P. P., Luo, J., Agrawal, A. N., Srinagesh, H., Axtell, R., Zhang, H., Platten, M., Wyss-Coray, T. and Steinman, L. (2010) Angiotensin II sustains brain inflammation in mice via TGF-β. J. Clin. Invest. 120, 2782-2794
43. Min, L. J., Mogi, M., Iwanami, J., Sakata, A., Jing, F., Tsukuda, K., Ohshima, K. and Horiuchi, M. (2011) Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism. Hypertens. Res. 34, 773-778
44. Abbott, N. J., Rönnbäck, L. and Hansson, E. (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41-53
45. 1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology. 36, 857-870
46. Badaut, J., Nehlig, A., Verbavatz, J., Stoeckel, M., Freund-Mercier, M. J. and Lasbennes, F. (2000) Hypervascularization in the magnocellular nuclei of the rat hypothalamus: relationship with the distribution of aquaporin-4 and markers of energy metabolism. J. Neuroendocrinol. 12, 960-969
47. Pavlov, V. A. and Tracey, K. J. (2004) Neural regulators of innate immune responses and inflammation. Cell. Mol. Life Sci. 61, 2322-2331
48. Cailotto, C., Costes, L. M., van der Vliet, J., VAN Bree, S. H., VAN Heerikhuize, J. J., Buijs, R. M. and Boeckxstaens, G. E. (2011) Neuroanatomical evidence demonstrating the existence of the vagal anti-inflammatory reflex in the intestine. Neurogastroenterol. Motil. 24, 191-e93
49. Hansen, M. K., Nguyen, K. T., Fleshner, M., Goehler, L. E., Gaykema, R. P., Maier, S. F. and Watkins, L. R. (2000) Effects of vagotomy on serum endotoxin, cytokines, and corticosterone after intraperitoneal lipopolysaccharide. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278, R331-R336
50. Metz, C. N. and Tracey, K. J. (2005) It takes nerve to dampen inflammation. Nat. Immunol. 6, 756-757
51. Jayaraman, T., Paget, A., Shin, Y. S., Li, X., Mayer, J., Chaudhry, H., Niimi, Y., Silane, M. and Berenstein, A. (2008) TNF-α-mediated inflammation in cerebral aneurysms: a potential link to growth and rupture. Vasc. Health Risk. Manag. 4, 805-817
52. Letiembre, M., Liu, Y., Walter, S., Hao, W., Pfander, T., Wrede, A., Schulz-Schaeffer, W. and Fassbender, K. (2009) Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol. Aging. 30, 759-768
53. Hyakkoku, K., Hamanaka, J., Tsuruma, K., Shimazawa, M., Tanaka, H., Uematsu, S., Akira, S., Inagaki, N., Nagai, H. and Hara, H. (2010) Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience. 171, 258-267
54. Edvinsson, L., MacKenzie, E. T. and McCulloch, J. (1993) Cerebral Blood Flow and Metabolism, Raven Press, New York
55. Goldstein, L. B., Bushnell, C. D., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G. et al. (2011) Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 42, 517-584
56. Pacak, K., Palkovits, M., Yadid, G., Kvetnansky, R., Kopin, I. J. and Goldstein, D. S. (1998) Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. Am. J. Physiol. 275, R1247-R1255
57. Kvetnansky, R., Sabban, E. L. and Palkovits, M. (2009) Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol. Rev. 89, 535-606
58. Grippo, A. J. and Johnson, A. K. (2009) Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress. 12, 1-21
59. Skrbic, R. and Igic, R. (2009) Seven decades of angiotensin (1939-2009). Peptides. 30, 1945-1950
60. Siragy, H. M. (2009) The potential role of the angiotensin subtype 2 receptor in cardiovascular protection. Curr. Hypertens. Rep. 1, 260-262
61. Tsutsumi, K. and Saavedra, J. M. (1991) Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am. J. Physiol. 261, R209-R216
62. de Gasparo, M. and Siragy, H. M. (1999) The AT2 receptor: fact, fancy and fantasy. Regul. Pept. 81, 11-24
63. Allen, A. M., MacGregor, D. P., McKinley, M. J. and Mendelsohn, F. A. (1999) Angiotensin II receptors in the human brain. Regul. Pept. 79, 1-7
64. Saavedra, J. M. (2005) Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell. Mol. Neurobiol. 25, 485-512
65. Porrello, E. R., Delbridge, L. M. and Thomas, W. G. (2009) The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front. Biosci. 14, 958-972
66. Rompe, F., Unger, T. and Steckelings, U. M. (2010) The angiotensin AT2 receptor in inflammation. Drug News Perspect. 23, 104-111
67. Xu, P., Sriramula, S. and Lazartigues, E. (2011) ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300, R804-R817
68. Saavedra, J. M. (1992) Brain and pituitary Angiotensin. Endocr. Rev. 13, 329-380
69. Paul, M., Mehr, A. P. and Kreutz, R. (2006) Physiology of local renin Angiotensin systems. Physiol. Rev. 86, 747-803
70. Bader, M. (2010) Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Ann. Rev. Pharm. Tox. 50, 439-465
71. Phillips, M. I. and de Oliveira, E. M. (2008) Brain renin angiotensin in disease. J. Mol. Med. 86, 715-722
72. Saavedra, J. M. and Pavel, J. (2005) Angiotensin II AT1 receptor antagonists inhibit the angiotensin-CRF-AVP axis and are potentially useful for the treatment of stress-related and mood disorders. Drug Dev. Res. 65, 237-269
73. Chappell, M. (2007) Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis: more than regulation of blood pressure? Hypertension 50, 596-599
74. Barnes, G., Japp, A. G. and Newby, D. E. (2010) Translational promise of the apelin-APJ system. Heart. 96, 1011-1016
75. Cuadra, A. E., Shan, Z., Sumners, C. and Raizada, M. K. (2010) A current view of brain renin-angiotensin system: is the (pro)renin receptor the missing link? Pharm. Ther. 125, 27-38
76. Horiuchi, M., Mogi, M. and Iwai, M. (2010) The angiotensin II type 2 receptor in the brain. JRAAS. 11, 1-6
77. Marc, Y. and Llorens-Cortes, C. (2011) The role of the brain renin-angiotensin system in hypertension: implications for new treatment. Prog. Neurobiol. 95, 89-103
78. 1 receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders. Cell. Mol. Neurobiol. 32, 667-681
79. Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A. and Smith, R. D. (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45, 205-251
80. Anderson, C., Teo, K., Gao, P., Arima, H., Dans, A., Unger, T., Commerford, P., Dyal, L., Schumacher, H., Pogue, J. et al. (2011) Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 10, 43-53
81. Zhou, J., Pavel, J., Macova, M., Yu, Z. X., Imboden, H., Ge, L., Nishioku, T., Dou, J., Delgiacco, E. and Saavedra, J. M. (2006) AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke. 37, 1271-1276
82. O'Callaghan, E. L., Bassi, J. K., Porrello, E. R., Delbridge, L. M., Thomas, W. G. and Allen, A. M. (2011) Regulation of angiotensinogen by angiotensin II in mouse primary astrocyte cultures. J. Neurochem. 119, 18-26
83. Miyoshi, M., Miyano, K., Moriyama, N., Taniguchi, M. and Watanabe, T. (2008) Angiotensin type 1 receptor antagonist inhibits lipopolysaccharide-induced stimulation of rat microglial cells by suppressing nuclear factor κB and activator protein-1 activation. Eur. J. Neurosci. 27, 343-351
84. Li, J. J., Lu, J., Kaur, C., Sivakumar, V., Wu, CY. and Ling, E. A. (2009) Expression of angiotensin II and its receptors in the normal and hypoxic amoeboid microglial cells and murine BV-2 cells. Neuroscience. 158, 1488-1499
85. Saavedra, J. M., Benicky, J. and Zhou, J. (2006) Angiotensin II: multitasking in the brain. J. Hypertens. Suppl. 24, S131-S137
86. Marvar, P. J., Lob, H., Vinh, A., Zarreen, F. and Harrison, D. G. (2011) The central nervous system and inflammation in hypertension. Curr. Opin. Pharmacol. 11, 156-161
87. Umemura, T., Kawamura, T., Umegaki, H., Mashita, S., Kanai, A., Sakakibara, T., Hotta, N. and Sobue, G. (2011) Endothelial and inflammatory markers in relation to progression of ischaemic cerebral small-vessel disease and cognitive impairment: a 6-year longitudinal study in patients with type 2 diabetes mellitus. J. Neurol. Neurosurg. Psychiatry. 82, 1186-1194
88. Paulson, O. B. and Waldemar, G. (1991) Role of the local renin-angiotensin system in the autoregulation of the cerebral circulation. Blood Vessels. 28, 231-235
89. Vraamak, T., Waldemar, G., Stradgaard, S. and Paulson, S. (1995) Angiotensin II receptor antagonist CV-11974 and cerebral blood flow autoregulation. J. Hypertens. 13, 755-761
90. Saavedra, J. M. and Nishimura, Y. (1999) Angiotensin and cerebral blood flow. Cell. Mol. Neurobiol. 19, 553-573
91. Castrén, E. and Saavedra, J. M. (1988) Repeated stress increases the density of angiotensin II binding sites in rat paraventricular nucleus and subfornical organ. Endocrinology. 122, 370-372
92. Aguilera, G., Young, W. S., Kiss, A. and Bathia, A. (1995) Direct regulation of hypothalamic corticotropin-releasing-hormone neurons by angiotensin II. Neuroendocrinology. 61, 437-444
93. Jezova, D., Ochedalski, T., Kiss, A. and Aguilera, G. (1998) Brain angiotensin II modulates sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. J. Neuroendocrinol. 10, 67-72
94. 2 receptors. Neuroendocrinology. 75, 227-240
95. Saavedra, J. M. and Benicky, J. (2007) Brain and peripheral angiotensin II play a major role in stress. Stress. 10, 185-193
96. 1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland. Brain Behav. Immun. 23, 945-957
97. 1 antagonist. Stroke. 33, 2297-2303
98. 1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke. 35, 1726-1731
99. 1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J. Cereb. Blood Flow Metab. 25, 878-886
100. Rodrigues, S. F. and Granger, D. N. (2011) Cerebral microvascular inflammation in DOCA salt-induced hypertension: role of angiotensin II and mitochondrial superoxide. J. Cereb. Blood Flow Metab. 32, 368-375
101. Iwanami, J., Mogi, M., Tsukuda, K., Min, L. J., Sakata, A., Jing, F., Iwai, M. and Horiuchi, M. (2010) Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-γ activation in diabetic mice. J. Hypertens. 28, 1730-1737
102. 1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J. Cereb. Blood Flow Metab. 24, 536-547
103. Schulz, R. and Heusch, G. (2006) Angiotensin II type 1 receptors in cerebral ischaemia-reperfusion: initiation of inflammation. J. Hypertens. Suppl. 24, S123-S129
104. 1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J. Pharmacol. Exp. Ther. 322, 1051-1058
105. Timaru-Kast, R., Wyschkon, S., Luh, C., Schaible, E. V., Lehmann, F., Philipp Merk, P., Werner, C., Engelhard, K. and Thal, S. C. (2012) Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma. Crit. Care Med. 40, 935-944
106. 1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R1376-R1384
107. 1 receptor inhibition. J. Cereb. Blood Flow Metab. 23, 371-380
108. 1 receptor/nuclear factor-κB pathway in brain microvascular endothelial cells. Life Sci. 78, 1293-1298
109. 1 receptor in brain endothelial cells. J. Cereb. Blood Flow Metab. 29, 640-647
110. Mehta, P. K. and Griendling, K. K. (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292, C82-C97
111. Lu, Y. and Wahl, L. M. (2005) Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF-κB activity in lipopolysaccharide-activated human primary monocytes. J Immunol. 175, 5423-5429
112. Dandona, P., Kumar, V., Aljada, A., Ghanim, H., Syed, T., Hofmayer, D., Mohanty, P., Tripathy, D. and Garg, R. (2003) Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-κB, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J. Clin. Endocrinol. Metab. 88, 4496-4501
113. Zhang, M., Mao, Y., Ramirez, S. H., Tuma, R. F. and Chabrashvili, T. (2010) Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience. 171, 852-858
114. 1 receptors. Brain Res. 871, 29-38
115. 1 receptor blockers. J. Cardiovasc. Pharmacol. 41, 593-599
116. Shimizu, H., Miyoshi, M., Matsumoto, K., Goto, O., Imoto, T. and Watanabe, T. (2004) The effect of central injection of angiotensin-converting enzyme inhibitor and the angiotensin type 1 receptor antagonist on the induction by lipopolysaccharide of fever and brain interleukin-1β response in rats. J. Pharmacol. Exp. Ther. 308, 865-873
117. 1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats. Brain Res. 1028, 9-18
118. Li, Z., Bains, J. S. and Ferguson, A. V. (1993) Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Brain Res. Bull. 30, 33-39
119. Gohlke, P., Weiss, S., Jansen, A., Wienen, W., Stangier, J., Rascher, W., Culman, J. and Unger, T. (2001) AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J. Pharmacol. Exp. Ther. 298, 62-70
120. Grippo, A. J., Kirby, R. F., Beltz, T. G. and Johnson, AK. (2002) Angiotensin II-induced drinking and pressor responses to central or systemic irbesartan and losartan. Pharmacol. Biochem. Behav. 71, 139-146
121. Sironi, L., Gelosa, P., Guerrini, U., Banfi, C., Crippa, V., Brioschi, M., Gianazza, E., Nobili, E., Gianella, A., de Gasparo, M. and Tremoli, E. (2004) Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J. Pharmacol. Exp. Ther. 311, 989-995
122. 1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 31, 2478-2486
123. Danielyan, L., Klein, R., Hanson, L., Buadze, M., Schwab, M., Gleiter, C. H. and Frey, W. H. (2010) Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 13, 195-201
124. Benicky, J., Sánchez-Lemus, E., Pavel, J. and Saavedra, J. M. (2009) Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell. Mol. Neurobiol. 29, 781-792
125. Hallevi, H., Hazan-Halevy, I. and Paran, E. (2007) Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. Eur. J. Neurol. 14, 1002-1007
126. 1 receptor blocker candesartan-induced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion. Neurochem. Res. 32, 1314-1321
127. Wu, X., Kihara, T., Hongo, H., Akaike, A., Niidome, T. and Sugimoto, H. (2010) Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion. Br. J. Pharmacol. 161, 33-50
128. Pedreañez, A., Arcaya, J. L, Carrizo, E. and Mosquera, J. (2006) Forced swimming test increases superoxide anion positive cells and angiotensin II positive cells in the cerebrum and cerebellum of the rat. Brain Res. Bull. 71, 18-22
129. 2 receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats. Stress. 11, 457-466
130. Edwards, E., King, J. A. and Fray, J. C. (1999) Increased basal activity of the HPA axis and renin-angiotensin system in congenital learned helpless rats exposed to stress early in development. Int. J. Dev. Neurosci. 17, 805-812
131. 1 receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation stress. Endocrinology. 142, 3880-3889
132. 1 receptor antagonism prevent stress-induced gastric injury. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G414-G423
133. Tsukuda, K., Mogi, M., Iwanami, J., Min, L. J., Sakata, A., Jing, F., Iwai, M. and Horiuchi, M. (2009) Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension. 54, 782-787
134. Miura, S., Karnik, S. S. and Saku, K. (2011) Angiotensin II type 1 receptor blockers: class effects versus molecular effects. JRAAS. 12, 1-7
135. 1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol. Cell. Endocrinol. 302, 237-243
136. Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A. and Kurtz, T. W. (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ -modulating activity. Hypertension. 43, 993-1002
137. Marshall, T. G., Lee, R. E. and Marshall, F. E. (2006) Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor. Biol. Med. Model. 3, 1
138. Erbe, D. V., Gartrell, K., Zhang, Y. -L., Suri, V., Kirincich, S. J., Will, S., Perreault, M., Wang, S. and Tobin, J. F. (2006) Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists. Vasc. Pharm. 45, 154-162
139. Neldam, S. (2010) Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both? Future Cardiol. 6, 129-135
140. An, J., Nakajima, T., Kuba, K. and Kimura, A. (2010) Losartan inhibits LPS-induced inflammatory signaling through a PPARγ -dependent mechanism in human THP-1 macrophages. Hypertens. Res. 33, 831-835
141. Rotman, N. and Wahli, W. (2010) PPAR modulation of kinase-linked receptor signaling in physiology and disease. Physiology. 25, 176-185
142. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. and Glass, C. K. (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391, 79-82
143. Wang, P., Anderson, P. O., Chen, S., Paulsson, K. M., Sjögren, H. O. and Li, S. (2001) Inhibition of the transcription factors AP-1 and NF-κB in CD4 T cells by peroxisome proliferator-activated receptor γ ligands. Int. Immunopharmacol. 1, 803-812
144. Xiao, J., Leung, J. C., Chan, L. Y., Tang, S. C. and Lai, K. N. (2009) Crosstalk between peroxisome proliferator-activated receptor-γ and angiotensin II in renal tubular epithelial cells in IgA nephropathy. Clin. Immunol. 132, 266-276
145. Ji, Y., Liu, J., Wang, Z., Liu, N. and Gou, W. (2009) PPARγ agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab. Invest. 89, 887-902
146. Zhao, S. M., Shen, L. H., Li, H. W., Wang, L., Chen, H., Wang, Y. L. and Guo, CY. (2008) Down-regulation of the expression of angiotensin II type 1 receptor in neonatal rat cardiac fibroblast by activation of PPARγ signal pathway. Chin. J. Physiol. 51, 357-362
147. Tham, D. M., Martin-McNulty, B., Wang, Y. X., Wilson, DW., Vergona, R., Sullivan, M. E., Dole, W. and Rutledge, J. C. (2002) Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs. Physiol. Genomics. 11, 21-30
148. 1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARγ Eur.J. Pharmacol. 552, 112-122
149. Pang, T., Benicky, J., Wang, J., Orecna, M., Sanchez-Lemus, E. and Saavedra, J. M. (2012) Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes. J. Hypertens. 30, 87-96
150. Schwartz, E. A., Zhang, W. Y., Karnik, S. K., Borwege, S., Anand, V. R., Laine, P. S., Su, Y. and Reaven, P. D. (2010) Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler., Thromb., Vasc. Biol. 30, 802-808
151. Morawietz, H. (2007) LOX-1 and atherosclerosis: proof of concept in LOX-1-knockout mice. Circ. Res. 100, 1534-1536
152. Mizuno, C. S., Chittiboyina, A. G., Shah, F. H., Patny, A., Kurtz, T. W., Pershadsingh, H. A., Speth, R. C., Karamyan, V. T., Carvalho, P. B. and Avery, M. A. (2010) Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome. J. Med. Chem. 53, 1076-1085
153. Goebel, M., Wolber, G., Markt, P., Staels, B., Unger, T., Kintscher, U. and Gust, R. (2010) Characterization of new PPARγ agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode. Bioorg. Med. Chem. 18, 5885-5895
154. Reid, J. L. (2005) Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? JRAAS 6, 15-24
155. Grammas, P., Martinez, J. and Miller, B. (2011) Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev. Mol. Med. 13, e19
156. Kasahara, Y., Taguchi, A., Uno, H., Nakano, A., Nakagomi, T., Hirose, H., Stern, D. M. and Matsuyama, T. (2010) Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia. Brain Res. 1340, 70-80
157. Fogari, R. and Zoppi, A. (2004) Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging. 21, 377-393
158. Devereux, R. B. and Dahlöf, B. (2007) Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Curr. Med. Res. Opin. 23, 443-457
159. Anderson, C. (2010) More indirect evidence of potential neuroprotective benefits of angiotensin receptor blockers. J. Hypertens. 28, 429
160. Tedesco, M. A., Ratti, G., Mennella, S., Manzo, G., Grieco, M., Rainone, A. C., Iarussi, D. and Iacono, A. (1999) Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am. J. Hypertens. 12, 1130-1134
161. Chrysant, S. G., Chrysant, G. S., Chrysant, C. and Shiraz, M. (2010) The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade. Curr. Clin. Pharmacol. 5, 89-95
162. Matsumoto, S., Shimodozono, M., Miyata, R. and Kawahira, K. (2010) The Angiotensin II type 1 receptor antagonist olmesartan preserves cerebral blood flow and cerebrovascular reserve capacity, and accelerates rehabilitative outcomes in hypertensive patients with a history of stroke. Int. J. Neurosci. 120, 372-380
163. Hong, K. S., Kang, D. W., Bae, H. J., Kim, Y. K., Han, M. K., Park, J. M., Rha, J. H., Lee, Y. S., Koo, J. S., Cho, Y. J. et al. (2010) Effect of cilnidipine vs. losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial. Acta Neurol. Scand. 121, 51-57
164. Schrader, J., Kulschewski, A. and Dendorfer, A. (2007) Inhibition of the renin-angiotensin system and the prevention of stroke. Am. J. Cardiovasc. Drugs. 7, 25-37
165. Moretti, A., Gorini, A. and Villa, R. F. (2011) Pharmacotherapy and prevention of vascular dementia. CNS Neurol. Disord. Drug Targets. 10, 370-390
166. Thöne-Reineke, C., Steckelings, U. M. and Unger, T. (2006) Angiotensin receptor blockers and cerebral protection in stroke. J. Hypertens. Suppl. 24, S115-S121
167. Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y. and Martin, R. M. (2011) Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J. Alzheimer's Dis. 26, 699-708
168. Farsang, C. (2011) Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc. Health Risk Manage. 7, 605-622
169. Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R. and Raz, I. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860
170. Konstam, M. A., Neaton, J. D., Dickstein, K., Drexler, H., Komajda, M., Martinez, F. A., Riegger, G. A., Malbecq, W., Smith, R. D., Guptha, S. and Poole-Wilson, P. A. (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 374, 1840-1848
171. Wolkowitz, O. M., Epel, E. S., Reus, V. I. and Mellon, S. H. (2010) Depression gets old fast: do stress and depression accelerate cell aging? Depression Anxiety 27, 327-338
172. Miller, K. R. and Streit, W. J. (2007) The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biol. 3, 245-253
173. Lartaud, I., Makki, T., Bray-des-Boscs, L., Niederhoffer, N., Atkinson, J., Corman, B. and Capdeville-Atkinson, C. (1994) Effect of chronic Ang I-converting enzyme inhibition on aging processes. IV. Cerebral blood flow regulation. Am. J. Physiol. 267, R687-R694
174. 1 receptor blockade prolongs the lifespan of spontaneously hypertensive rats and reduces stress-induced release of catecholamines, glucocorticoids, and vasopressin. Ann. N.Y. Acad. Sci. 1018, 131-136
175. Benigni, A., Corna, D., Zoja, C., Sonzogni, A., Latini, R., Salio, M., Conti, S., Rottoli, D., Longaretti, L., Cassis, P. et al. (2009) Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 119, 524-530
176. 1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. Am. J. Physiol. Heart Circ. Physiol. 293, H1327-H1333
177. Linz, W., Heitsch, H., Schölkens, B. A. and Wiemer, G. (2000) Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension. 35, 908-913
178. 1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Exp. Rev. Neurother. 9, 1413-1431
179. Fogari, R., Mugellini, A., Zoppi, A., Marasi, G., Pasotti, C., Poletti, L., Rinaldi, A. and Preti, P. (2004) Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur. J. Clin. Pharmacol. 59, 863-868
180. Duron, E. and Hanon, O. (2010) Antihypertensive treatments, cognitive decline, and dementia. J. Alzheimer's Dis. 20, 903-914
181. Hajjar, I., Catoe, H., Sixta, S., Boland, R., Johnson, D., Hirth, V., Wieland, D. and Eleazer, P. (2005) Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J. Gerontol. A. Biol. Sci. Med. Sci. 60, 67-73
182. Trenkwalder, P. (2006) The Study on Cognition and Prognosis in the Elderly (SCOPE) recent analyses. J. Hypertens. Suppl. 24, S107-S114
183. Stewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A. et al. (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11, 155-161
184. Holmes, C. and Cotterell, D. (2009) Role of infection in the pathogenesis of AD: implications for treatment. CNS Drugs. 23, 993-1002
185. Honjo, K., van Reekum, R. and Verhoeff, N. P. (2009) Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimer's Dementia 5, 348-360
186. Kamer, A. R., Dasanayake, A. P., Craig, R. G., Glodzik-Sobanska, L., Bry, M. and de Leon, M. J. (2008) Alzheimer's disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis. J. Alzheimer's Dis. 13, 437-449
187. Denny, J. B., Polan-Curtain, J., Wayner, M. J. and Armstrong, D. L. (1991) Angiotensin II blocks hippocampal long-term potentiation. Brain Res. 567, 321-324
188. Wayner, M. J., Armstrong, D. L., Polan-Curtain, J. L. and Denny, J. B. (1993) Role of angiotensin II and AT1 receptors in hippocampal LTP. Pharmacol. Biochem. Behav. 45, 455-464
189. Gard, P. R. (2002) The role of angiotensin II in cognition and behaviour. Eur. J. Pharmacol. 438, 1-14
190. 1 receptor subtype in the effects of angiotensin IV and LVVhaemorphin 7 on hippocampal neurotransmitter levels and spatial working memory. J. Neurochem. 112, 1223-1234
191. Barnes, J. M., Barnes, N. M., Costall, B., Horovitz, Z. P., Ironside, J. W., Naylor, R. J. and Williams, T. J. (1990) Angiotensin II inhibits cortical cholinergic function: implications for cognition. J. Cardiovasc. Pharmacol. 16, 234-238
192. Raghavendra, V., Chopra, K. and Kulkarni, S. K. (1998) Involvement of cholinergic system in losartan induced facilitation of spatial and short-term working memory. Neuropeptides. 32, 417-421
193. Zhu, D., Shi, J., Zhang, Y., Wang, B., Liu, W., Chen, Z. and Tong, Q. (2011) Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. PLoS ONE 6, e16037
194. Takeda, S., Sato, N., Takeuchi, D., Kurinami, H., Shinohara, M., Niisato, K., Kano, M., Ogihara, T., Rakugi, H. and Morishita, R. (2009) Angiotensin receptor blocker prevented β-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension. 54, 1345-1352
195. Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., Humala, N., Seror, I., Bartholomew, S., Rosendorff, C. and Pasinetti, G. M. (2007) Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 117, 3393-3402
196. Ferrington, L., Miners, J. S., Palmer, L. E., Bond, S. M., Povey, J. E., Kelly, P. A., Love, S., Horsburgh, K. J. and Kehoe, P. G. (2011) Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease. Am. J. Transl. Res. 3, 197-208
197. 1 receptors in memory deficit induced by intracerebral streptozotocin. Behav. Brain Res. 199, 235-240
198. Li, N. C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E. and Wolozin, B. (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340, b5465
199. Holzboer, F. and Barden, N. (1996) Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 17, 187-205
200. Pariante, C. M. and Lightman, S. L. (2008) The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 31, 464-468
201. Alexopoulos, G. S., Meyers, B. S., Young, R. C., Campbell, S., Silbersweig, D. and Charlson, M. (1997) 'Vascular depression' hypothesis. Arch. Gen. Psychiatry. 54, 915-922
202. Holley, C., Murrell, S. A. and Mast, B. T. (2006) Psychosocial and vascular risk factors for depression in the elderly. Am. J. Geriatr. Psychiatry. 14, 84-90
203. Culang-Reinlieb, M. E., Johnert, L. C., Brickman, A. M., Steffens, D. C., Garcon, E. and Sneed, J. R. (2010) MRI defined vascular depression: a review of the construct. Int. J. Geriatr. Psychiatry. 26, 1101-1108
204. Anisman, H., Merali, Z. and Hayley, S. (2008) Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog. Neurobiol. 85, 1-74
205. Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B. et al. (2011) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35, 804-817
206. Krishnan, V. and Nestler, E. J. (2010) Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry. 167, 1305-1320
207. Yang, G., Xi, Z. X., Wan, Y., Wang, H. and Bi, G. (1993) Changes in circulating and tissue angiotensin II during acute and chronic stress. Biol. Signals. 2, 166-172
208. Armando, I., Volpi, S., Aguilera, G. and Saavedra, J. M. (2007) Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. Brain Res. 1142, 92-99
209. 1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology. 31, 1123-1134
210. Kaiser, F. C., Palmer, G. C., Wallace, A. V., Carr, R. D., Fraser-Rae, L. and Hallam, C. (1992) Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-maze. NeuroReport. 3, 922-924
211. Shekhar, A., Johnson, P. L., Sajdyk, T. J., Fitz, S. D., Keim, S. R., Kelley, P. E., Gehlert, D. R. and DiMicco, J. A. (2006) Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus. J. Neurosci. 26, 9205-9215
212. Gard, P. R., Mandy, A. and Sutcliffe, M. A. (1999) Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biol. Psychiatry. 45, 1030-1034
213. Pedreañez, A., Arcaya, J. L., Carrizo, E., Rincón, J., Viera, N., Peña, C., Vargas, R. and Mosquera, J. (2011) Experimental depression induces renal oxidative stress in rats. Physiol. Behav. 104, 1002-1009
214. Martin, P., Massol, J. and Puech, A. J. (1990) Captopril as an antidepressant? Effects on the learned helplessness paradigm in rats. Biol. Psychiatry. 27, 968-974
215. Keck, M. E. and Holsboer, F. (2001) Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides. 22, 835-844
216. Hlavacova, N., Wes, P. D., Ondrejcakova, M., Flynn, M. E., Poundstone, P. K., Babic, S., Murck, H. and Jezova, D. (2012) Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int. J. Neuropsychopharmacol. 15, 247-265
217. Hlavacova, N., Bakos, J. and Jezova, D. (2010) Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release. J. Psychopharmacol. 24, 779-786
218. Koo, J. W., Russo, S. J., Ferguson, D., Nestler, E. J. and Duman, R. S. (2010) Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc. Natl. Acad.Sci. U.S.A. 107, 2669-2674
219. Young, E. A., Lopez, J. F., Murphy-Weinberg, V., Watson, S. J. and Akil, H. (2003) Mineralocorticoid receptor function in major depression. Arch. Gen. Psychiatry. 60, 24-28
220. Emanuele, E., Geroldi, D., Minoretti, P., Coen, E. and Politi, P. (2005) Increased plasma aldosterone in patients with clinical depression. Arch. Med. Res. 36, 544-548
221. Frasure-Smith, N., Lespérance, F., Irwin, M. R., Talajic, M. and Pollock, B. G. (2009) The relationships among heart rate variability, inflammatory markers and depression in coronary heart disease patients. Brain Behav. Immun. 23, 1140-1147
222. Braszko, J. J., Karwowska-Polecka, W., Halicka, D. and Gard, P. R. (2003) Captopril and enalapril improve cognition and depressed mood in hypertensive patients. J. Basic Clin. Physiol. Pharmacol. 14, 323-343
223. Weber, M. A. (2005) Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes. Manage. Care Interface. 18, 47-54
224. Hertzman, M., Adler, L. W., Arling, B. and Kern, M. (2005) Lisinopril may augment antidepressant response. J. Clin. Psychopharmacol. 25, 618-620
225. Palma Gámiz, J. L., Pego, M., Contreras, E. M., Anglada, M. P., Martinez, J. O., Esquerra, E. A. and Sagastagoitia Gorostiza, J. D. (2006) A twelve-week, multicenter, randomized, double-blind, parallelgroup, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH). Clin. Ther. 28, 2040-2051
226. Julius, S., Nesbitt, S. D., Egan, B. M., Weber, M., Michelson, E. L., Kaciroti, N., Black, H. R., Grimm, R. H., Messerli, F. H., Oparil, S. et al. (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 354, 1-13
227. Chaturvedi, N., Porta, M., Klein, R., Orchard, T., Fuller, J., Parving, H. H., Bilous, R. and Sjolie, A. K. (2008) Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomized, placebo-controlled trials. Lancet. 372, 1394-1402
228. Pavlatou, M. G., Mastorakos, G., Lekakis, I., Liatis, S., Vamvakou, G., Zoumakis, E., Papassotiriou, I., Rabavilas, A. D., Katsilambros, N. and Chrousos, G. P. (2008) Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. Stress. 11, 62-72
229. Nasr, S. J., Crayton, J. W., Agarwal, B., Wendt, B. and Kora, R. (2011) Lower frequency of antidepressant use in patients on renin-angiotensin-aldosterone system modifying medications. Cell. Mol. Neurobiol. 31, 615-618
230. Wosik, K., Cayrol, R., Dodelet-Devillers, A., Berthelet, F., Bernard, M., Moumdjian, R., Bouthillier, A., Reudelhuber, T. L. and Prat, A. (2007) Angiotensin II controls occluding function and is required for blood-brain barrier maintenance: relevance to multiple sclerosis. J. Neurosci. 27, 9032-9042
231. Axtell, R. C. and Steinman, L. (2009) Gaining entry to an uninflamed brain. Nat. Immunol. 10, 453-455
232. Platten, M., Youssef, S., Hur, E. M., Ho, P. P., Han, M. H., Lanz, T. V., Phillips, L. K., Goldstein, M. J., Bhat, R., Raine, C. S. et al. (2009) Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 106, 14948-14953
233. Stegbauer, J., Lee, D. H., Seubert, S., Ellrichmann, G., Manzel, A., Kvakan, H. and Muller, D. N. (2009) Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 106, 14942-14947
234. Lühder, F., Lee, D. H., Gold, R., Stegbauer, J. and Linker, R. A. (2009) Small but powerful: short peptide hormones and their role in autoimmune inflammation. J. Neuroimmunol. 217, 1-7
235. Prasad, S., Sung, B. and Aggarwal, B. B. (2012) Age-associated chronic diseases require age-old medicine: role of chronic inflammation. Prev. Med. 54 (Suppl.), S29-S37
236. Lu, M. and Hu, G. (2011) Targeting metabolic inflammation in Parkinson's disease: Implications for prospective therapeutic strategies. Clin. Exp. Pharmacol. Physiol. 39, 577-585
237. Mertens, B., Vanderheyden, P., Michotte, Y. and Sarre, S. (2010) The role of the central renin-angiotensin system in Parkinson's disease. JRAAS. 11, 49-56
238. Joglar, B., Rodriguez-Pallares, J., Rodriguez-Perez, A. I., Rey, P., Guerra, M. J. and Labandeira-Garcia, J. L. (2009) The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 109, 656-669
239. 2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur. J. Pharmacol. 297, 299-306
240. 1 receptor antagonist, L-158,809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment. Int. J. Radiat. Oncol. Biol. Phys. 73, 499-505
241. Jenrow, K. A., Brown, S. L., Liu, J., Kolozsvary, A., Lapanowski, K. and Kim, J. H. (2010) Ramipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrus. Radiat. Oncol. 5,6
242. Maas, A. I., Roozenbeek, B. and Manley, G. T. (2010) Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics. 7, 115-126
243. Meyer, M. J., Megyesi, J., Meythaler, J., Murie-Fernandez, M., Aubut, J. A., Foley, N., Salter, K., Bayley, M., Marshall, S. and Teasell, R. (2010) Acute management of acquired brain injury part II: an evidence-based review of pharmacological interventions. Brain Inj. 24, 706-721
244. Nag, S. and Kilty, D. W. (1997) Cerebrovascular changes in chronic hypertension. Protective effects of enalapril in rats. Stroke. 28, 1028-1034
245. Ilieva, I., Ohgami, K., Jin, X. H., Suzuki, Y., Shiratori, K., Yoshidam, K., Kasem, S. and Ohno, S. (2006) Captopril suppresses inflammation in endotoxin-induced uveitis in rats. Exp. Eye Res. 83, 651-657
246. Munoz, A., Rey, P., Guerra, M. J., Mendez-Alvarez, E., Soto-Otero, R. and Labandeira-Garcia, J. L. (2006) Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology. 51, 112-120
247. Nayak, V. and Patil, P. A. (2008) Antidepressant activity of fosinopril, ramipril and losartan, but not of lisinopril in depressive paradigms of albino rats and mice. Indian J. Exp. Biol. 46, 180-184
248. Arima, H. and Chalmers, J. (2011) PROGRESS: prevention of recurrent stroke. J. Clin. Hypertens. 13, 693-702
249. Breckenridge, A. (1991) Angiotensin converting enzyme inhibitors and quality of life. Am. J. Hypertens. 4, 79S-82S
250. Yodfat, Y., Bar-On, D., Amir, M. and Cristal, N. (1996) Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study. J. Hum Hypertens. 10, 117-122
251. Kehoe, P. G., Miners, S. and Love, S. (2009) Angiotensins in Alzheimer's disease: friend or foe? Trends Neurosci. 32, 619-628
252. Izzo, Jr, J. L. and Weir, M. R. (2011) Angiotensin-converting enzyme inhibitors. J. Clin. Hypertens. 13, 667-675
253. Otte, C., Hinkelmann, K., Moritz, S., Yassouridis, A., Jahn, H., Wiedemann, K. and Kellner, M. (2010) Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J. Psychiatr. Res. 44, 339-346
254. Leibovitz, E. and Schiffrin, E. L. (2001) PPAR activation: a new target for the treatment of hypertension. J. Cardiovasc. Pharmacol. 50, 120-125
255. Duan, S. Z., Usher, M. G. and Mortensen, R. M. (2009) PPARs: the vasculature, inflammation and hypertension. Curr. Opin. Nephrol. Hypertens. 18, 128-133
256. Sundararajan, S., Jiang, Q., Heneka, M. and Landreth, G. (2006) PPARγ as a therapeutic target in central nervous system diseases. Neurochem. Int. 49, 136-144
257. Sodhi, R. K., Singh, N. and Jaggi, AS. (2011) Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease. Naunyn Schmiedebergs Arch. Pharmacol. 384, 115-124
258. Nissen, S. E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Eng. J. Med. 356, 2457-2471
259. Ciudin, A., Hernández, C. and Simó, R. (2012) Update on cardiovascular safety of PPARγ agonists and relevance to medicinal chemistry and clinical pharmacology. Curr. Top. Med. Chem. 12, 585-604
260. Geldmacher, D,S., Fritsch, T., McClendon, M. J. and Landreth, G. (2011) A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch. Neurol. 68, 45-50
261. Ryan, K. K., Li, B., Grayson, B. E., Matter, E. K., Woods, S. C. and Seeley, R. J. (2011) A role for central nervous system PPAR-γ in the regulation of energy balance. Nat. Med. 17, 623-626
262. Villacorta, L., Schopfer, F. J., Zhang, J., Freeman, B. A. and Chen, Y. E. (2009) PPARγ and its ligands: therapeutic implications in cardiovascular disease. Clin. Sci. 116, 205-218
263. Stafylas, P. C., Sarafidis, P. A. and Lasaridis, A. N. (2009) The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int. J. Cardiol. 131, 98-304